Prevalence, Characteristics, and Reasons for Kratom Use among Psychiatrically Ill Inpatients Who Use Substances

References

• Adzrago, D., Obekpa, E. O., Suragh, T. A., John, E. R., Yeh, P. G., Gallardo, K. R., & Wilkerson, J. M. (2022). Kratom use categories and their associations with co-occurring substance use and mental health disorder symptoms during the COVID-19 pandemic. Drug and Alcohol Dependence, 239, 109605. https://doi.org/10.1016/j.drugalcdep.2022.109605
   PubMed Web of Science ®Google Scholar
• American Kratom Association (AKA) (2019). The increase in consumer use of kratom in the United States. https://www.americankratom.org/images/Kratom_Population_2019.pdf.
   Google Scholar
• Bath, R., Bucholz, T., Buros, A. F., Singh, D., Smith, K. E., Veltri, C. A., & Grundmann, O. (2020). Self-reported health diagnoses and demographic correlates with Kratom use: Results from an online survey. Journal of Addiction Medicine, 14(3), 244–252. https://doi.org/10.1097/adm.0000000000000570
   PubMed Web of Science ®Google Scholar
• Botanical Education Alliance. (2016). Groups” DEA ban of natural hearb kratom could cause billions in industry losses, harm more than three million Americans. Cision: PR Newswire. https://www.prnewswire.com/news-releases/groups-dea-ban-of-natural-herb-kratom-could-cause-billions-in-industry-losses-harm-more-than-three-million-americans-300336610.html.
   Google Scholar
• Burke, D. J., Mahonski, S. G., & Van Cott, A. C. (2021). Breakthrough seizure associated with kratom use in patients with epilepsy. Neurology. Clinical Practice, 11(1), 78–84. https://doi.org/10.1212/cpj.0000000000000846
   PubMedGoogle Scholar
• Coe, M. A., Pillitteri, J. L., Sembower, M. A., Gerlach, K. K., & Henningfield, J. E. (2019). Kratom as a substitute for opioids: Results from an online survey. Drug and Alcohol Dependence, 202, 24–32. https://doi.org/10.1016/j.drugalcdep.2019.05.005
   PubMed Web of Science ®Google Scholar
• Covvey, J. R., Vogel, S. M., Peckham, A. M., & Evoy, K. E. (2020). Prevalence and characteristics of self-reported Kratom use in a representative US general population sample. Journal of Addictive Diseases, 38(4), 506–513. https://doi.org/10.1080/10550887.2020.1788914
   PubMed Web of Science ®Google Scholar
• Fawcett, T. (2006). An introduction to ROC analysis. Pattern Recognition Letters, 27(8), 861–874. https://doi.org/10.1016/j.patrec.2005.10.010
   Web of Science ®Google Scholar
• Garcia-Romeu, A., Cox, D. J., Smith, K. E., Dunn, K. E., & Griffiths, R. R. (2020). Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence, 208, 107849. https://doi.org/10.1016/j.drugalcdep.2020.107849
   PubMed Web of Science ®Google Scholar
• Grundmann, O. (2017). Patterns of kratom use and health impact in the US – Results from an online survey. Drug and Alcohol Dependence, 176, 63–70. https://doi.org/10.1016/j.drugalcdep.2017.03.007
   PubMed Web of Science ®Google Scholar
• Hamid, H. A., Ramli, A. N. M., & Yusoff, M. M. (2017). Indole alkaloids from plants as potential leads for antidepressant drugs: A mini review. Frontiers in Pharmacology, 8, 96. https://doi.org/10.3389/fphar.2017.00096
   PubMed Web of Science ®Google Scholar
• Idayu, N. F., Hidayat, M. T., Moklas, M. A. M., Sharida, F., Raudzah, A. R. N., Shamima, A. R., & Apryani, E. (2011). Antidepressant-like effect of mitragynine isolated from Mitragyna speciosa Korth in mice model of depression. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 18(5), 402–407. https://doi.org/10.1016/j.phymed.2010.08.011
   PubMed Web of Science ®Google Scholar
• Kumarnsit, E., Vongvatcharanon, U., Keawpradub, N., & Intasaro, P. (2007). Fos-like immunoreactivity in rat dorsal raphe nuclei induced by alkaloid extract of Mitragyna speciosa. Neuroscience Letters, 416(2), 128–132. https://doi.org/10.1016/j.neulet.2007.01.061
   PubMed Web of Science ®Google Scholar
• Lee, J., Terashima, J. P., & Parker, M. A. (2022). The association between E-cigarette use and Kratom use among US adults. Preventive Medicine, 164, 107295. https://doi.org/10.1016/j.ypmed.2022.107295
   PubMed Web of Science ®Google Scholar
• Mai, C., Qiu, L., Zeng, Y., & Tan, X. (2021). Lactobacillus casei strain shirota enhances the ability of geniposide to activate SIRT1 and decrease inflammation and oxidative stress in septic mice. Frontiers in Physiology, 12, 678838. https://doi.org/10.3389/fphys.2021.678838
   PubMed Web of Science ®Google Scholar
• Matsumoto, K., Mizowaki, M., Suchitra, T., Murakami, Y., Takayama, H., Sakai, S., Aimi, N., & Watanabe, H. (1996). Central antinociceptive effects of mitragynine in mice: Contribution of descending noradrenergic and serotonergic systems. European Journal of Pharmacology, 317(1), 75–81. https://doi.org/10.1016/S0014-2999(96)00714-5
   PubMed Web of Science ®Google Scholar
• Nahm, F. S. (2022). Receiver operating characteristic curve: Overview and practical use for clinicians. Korean Journal of Anesthesiology, 75(1), 25–36. https://doi.org/10.4097/kja.21209
   PubMed Web of Science ®Google Scholar
• Nicewonder, J. A., Buros, A. F., Veltri, C. A., & Grundmann, O. (2019). Distinct kratom user populations across the United States: A regional analysis based on an online survey. Human Psychopharmacology, 34(5), e2709. https://doi.org/10.1002/hup.2709
   PubMed Web of Science ®Google Scholar
• Palamar, J. J., Martins, S. S., Su, M. K., & Ompad, D. C. (2015). Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug and Alcohol Dependence, 156, 112–119. https://doi.org/10.1016/j.drugalcdep.2015.08.028
   PubMed Web of Science ®Google Scholar
• Palamar, J. J. (2021). Past-year kratom use in the U.S.: Estimates from a nationally representative sample. American Journal of Preventive Medicine, 61(2), 240–245. https://doi.org/10.1016/j.amepre.2021.02.004
   PubMed Web of Science ®Google Scholar
• Penders, T., & Stanciu, C. (2020). Kratom, a substance of increasing concern [PCSS webinar]. Providers Clinical Support System. November 28, 2018. https://doi.org/10.13140/rg.2.2.14422.50242
   Google Scholar
• Prozialeck, W. C., Avery, B. A., Boyer, E. W., Grundmann, O., Henningfield, J. E., Kruegel, A. C., McMahon, L. R., McCurdy, C. R., Swogger, M. T., Veltri, C. A., & Singh, D. (2019). Kratom policy: The challenge of balancing therapeutic potential with public safety. The International Journal on Drug Policy, 70, 70–77. https://doi.org/10.1016/j.drugpo.2019.05.003
   PubMed Web of Science ®Google Scholar
• Ramanathan, S., León, F., Chear, N. J. Y., Yusof, S. R., Murugaiyah, V., McMahon, L. R., & McCurdy, C. (2021). Kratom (Mitragyna speciosa Korth.): A description on the ethnobotany, alkaloid chemistry, and neuropharmacology. In A. Rahman (Eds.), Studies in natural products chemistry (vol. 69, pp. 195–225). Elsevier. https://doi.org/10.1016/b978-0-12-819487-4.00003-3
   Google Scholar
• Rogers, J. M., Smith, K. E., Strickland, J. C., & Epstein, D. H. (2021). Kratom use in the US: Both a regional phenomenon and a white middle-class phenomenon? Evidence from NSDUH 2019 and an online convenience sample. Frontiers in Pharmacology, 12, 789075. https://doi.org/10.3389/fphar.2021.789075
   PubMed Web of Science ®Google Scholar
• Saingam, D., Assanangkornchai, S., Geater, A. F., & Lerkiatbundit, S. (2014). Validation of Krathom (Mitragyna speciosa Korth.) Dependence Scale (KDS): A dependence screen for internationally emerging psychoactive substance. Substance Abuse, 35(3), 276–283. https://doi.org/10.1080/08897077.2014.924464
   PubMed Web of Science ®Google Scholar
• Schimmel, J., Amioka, E., Rockhill, K., Haynes, C. M., Black, J. C., Dart, R. C., & Iwanicki, J. L. (2021). Prevalence and description of kratom (Mitragyna speciosa) use in the United States: A cross-sectional study. Addiction, 116(1), 176–181. https://doi.org/10.1111/add.15082
   PubMed Web of Science ®Google Scholar
• Smith, K. E., Dunn, K. E., Grundmann, O., Garcia-Romeu, A., Rogers, J. M., Swogger, M. T., & Epstein, D. H. (2021). Social, psychological, and substance use characteristics of US adults who use kratom: Initial findings from an online, crowdsourced study. Experimental and Clinical Psychopharmacology, 30(6), 983–996. https://doi.org/10.1037/pha0000518
   PubMed Web of Science ®Google Scholar
• Smith, K. E., Dunn, K. E., Rogers, J. M., Grundmann, O., McCurdy, C. R., Garcia-Romeu, A., Schriefer, D., Swogger, M. T., & Epstein, D. H. (2022). Kratom use as more than a "self-treatment". The American Journal of Drug and Alcohol Abuse, 48(6), 684–694. PMID: 35767669. https://doi.org/10.1080/00952990.2022.2083967
   PubMed Web of Science ®Google Scholar
• Smith, K. E., Dunn, K. E., Rogers, J. M., Garcia-Romeu, A., Strickland, J. C., & Epstein, D. H. (2022). Assessment of Kratom use disorder and withdrawal among an online convenience sample of US adults. Journal of Addiction Medicine, 16(6), 666–670. https://doi.org/10.1097/ADM.0000000000000986
   PubMed Web of Science ®Google Scholar
• Stanciu, C., Ahmed, S., Hybki, B., Penders, T., & Galbis-Reig, D. (2021). Pharmacotherapy for management of “Kratom Use Disorder”: A systematic literature review with survey of experts. WMJ: official Publication of the State Medical Society of Wisconsin, 120(1), 54–61. PMID: 33974767.
   PubMedGoogle Scholar
• Stanciu, C., Ahmed, S., Gnanasegaram, S., Gibson, S., Penders, T., Grundmann, O., & McCurdy, C. (2022). Kratom as an opioid alternative: Harm, or harm reduction? A systematic review of literature. The American Journal of Drug and Alcohol Abuse, 48(5), 509–528. https://doi.org/10.1080/00952990.2022.2111685
   PubMed Web of Science ®Google Scholar
• Swets, J. A. (1988). Measuring the accuracy of diagnostic systems. Science, 240(4857), 1285–1293. https://doi.org/10.1126/science.3287615
   PubMed Web of Science ®Google Scholar
• Swogger, M. T., & Walsh, Z. (2018). Kratom use and mental health: A systematic review. Drug and Alcohol Dependence, 183, 134–140. https://doi.org/10.1016/j.drugalcdep.2017.10.012
   PubMed Web of Science ®Google Scholar
• Takayama, H. (2004). Chemistry and pharmacology of analgesic indole alkaloids from the Rubiaceous plant, Mitragyna speciosa. Chemical & Pharmaceutical Bulletin, 52(8), 916–928. https://doi.org/10.1248/cpb.52.916
   PubMed Web of Science ®Google Scholar
• Xu, K. Y., Mintz, C. M., Borodovsky, J. T., Glaser, P. E. A., Bierut, L. J., & Grucza, R. A. (2021). Prevalence of kratom use and co-occurring substance use disorders in the United States. The Primary Care Companion for CNS Disorders, 23(4), 35636. https://doi.org/10.4088/pcc.21br02930
   Google Scholar